Advertisement

Tumor Biology

, Volume 34, Issue 3, pp 1485–1491 | Cite as

Discussion of modifying stage IV gastric cancer based on Borrmann classification

  • Bin Yang
  • Guoqiang Wu
  • Xiaochen Wang
  • Xuefeng Zhang
Research Article

Abstract

This study aims to investigate the prognostic significance of reclassification of stage IV gastric cancers in conjunction with Borrmann type. A total of 1,673 gastric cancer patients who received a gastrectomy between 1980 and 2003 were retrospectively evaluated. Of the patients, 244 (14.58 %), 344 (20.56 %), 589 (35.21 %), and 496 (29.65 %) had stage I, II, III, and IV cancers, respectively. After Cox regression analysis, Borrmann type was identified to be the independent prognostic factor in stage IV gastric cancer. The disease-specific postoperative survival of patients with Borrmann I, II, and III tumors was clearly distinguished by TNM classification system (P < 0.05), while it failed to classify Borrmann IV tumors (P = 0.147). Interestingly, the disease-specific postoperative survival of stage IV patients with Borrmann IV tumors (group 1) was significantly poor than the cases with stage IV but not Borrmann IV tumors (group 2), as well as the patients with Borrmann IV while not included in stage IV tumors (group 3) (P = 0.022 and P = 0.000, respectively). Meanwhile, the disease-specific postoperative survival was not observed as significantly different between group 2 and group 3 (P = 0.063); furthermore, group 2 + 3 had a better prognosis than group 1 (introduced stage IVa vs. stage IVb; P = 0.006). Reclassification of stage IV through combining the present TNM classification system with Borrmann type may more accurately predict the prognosis of patients.

Keywords

Gastric cancer TNM category Borrmann classification Prognosis 

Notes

Acknowledgments

This study was funded by the China National Natural Science Foundation (nos. 81102029 and 81172047).

References

  1. 1.
    Shimoyama S, Seto Y, Yasuda H, Mafune K, Kaminishi M. Concepts, rationale, and current outcomes of less invasive surgical strategies for early gastric cancer: date from a quarter-century of experience in a single institution. World J Surg. 2005;29:58–65.PubMedCrossRefGoogle Scholar
  2. 2.
    Lindsey H. Preoperative chemoradiotherapy shows promise in gastric cancer. Lancet Oncol. 2004;5:519.PubMedCrossRefGoogle Scholar
  3. 3.
    Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27(6):851–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Ohtsu A, Yoshida S, Sajio N. Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol. 2006;24:2188–96.PubMedCrossRefGoogle Scholar
  5. 5.
    Adchi Y, Shiraishi N, Kitano S. Modern treatment of early gastric cancer: review of the Japanese experience. Dig Surg. 2002;19:333–9.CrossRefGoogle Scholar
  6. 6.
    Schwartz GK, Winter K, Minsky BD, Crane C, Thomson PJ, Anne P, et al. Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114). J Clin Oncol. 2009;27(12):1956–62.PubMedCrossRefGoogle Scholar
  7. 7.
    Küchler T, Bestmann B, Rappat S, Henne-Bruns D, Wood-Dauphinee S. Impact of psychotherapeutic support for patients with gastrointestinal cancer undergoing surgery: 10-year survival results of a randomized trial. J Clin Oncol. 2007;25(19):2702–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Yamashita K, Sakuramoto S, Kikuchi S, Katada N, Kobayashi N, Watanabe M. Validation of staging systems for gastric cancer. Gastric Cancer. 2008;11(2):111–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Hidaka H, Eto T, Maehara N, Jimi S, Hotokezaka M, Chijiiwa K. Comparative effect of lymph node metastasis classified by the anatomical site or by the number of nodes involved on prognosis of patients with gastric cancer. Hepatogastroenterology. 2008;55(88):2269–72.PubMedGoogle Scholar
  10. 10.
    Smith DD, Schwarz RR, Schwarz RE. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US-population database. J Clin Oncol. 2005;23(28):7114–24.PubMedCrossRefGoogle Scholar
  11. 11.
    Tiberio GA, Coniglio A, Marchet A, Marrelli D, Giacopuzzi S, Baiocchi L, et al. Metachronous hepatic metastases from gastric carcinoma: a multicentric survey. Eur J Surg Oncol. 2009;35(5):486–91.PubMedCrossRefGoogle Scholar
  12. 12.
    Huang B, Zheng X, Wang Z, Wang M, Dong Y, Zhao B, et al. Prognostic significance of the number of metastatic lymph nodes: is UICC/TNM node classification perfectly suitable for early gastric cancer? Ann Surg Oncol. 2009;16(1):61–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Nitti D, Marchet A, Mocellin S, Rossi GM, Ambrosi A, Mencarelli R. Prognostic value of subclassification of T2 tumours in patients with gastric cancer. Br J Surg. 2009;96(4):398–404.PubMedCrossRefGoogle Scholar
  14. 14.
    Sun Z, Zhu GL, Lu C, Guo PT, Huang BJ, Li K, et al. A novel subclassification of pT2 gastric cancers according to the depth of muscularis propria invasion: superficial muscularis propria versus deep muscularis propria/subserosa. Ann Surg. 2009;249(5):768–75.PubMedCrossRefGoogle Scholar
  15. 15.
    Kim DH, Oh CA, Oh SJ, Choi MG, Noh JH, Sohn TS, et al. Validation of seventh edition AJCC gastric cancer staging modifications. J Surg Oncol. 2012;105(1):26–30.PubMedCrossRefGoogle Scholar
  16. 16.
    Chen CY, Wu CW, Lo SS, Hsieh MC, Lui WY, Shen KH. Peritoneal carcinomatosis and lymph node metastasis are prognostic indicators in patients with Borrmann type IV gastric carcinoma. Hepatogastroenterology. 2002;49(45):874–7.PubMedGoogle Scholar
  17. 17.
    Kim DY, Kim HR, Kim YJ, Kim S. Clinicopathological features of patients with Borrmann type IV gastric carcinoma. ANZ J Surg. 2002;72(10):739–42.PubMedCrossRefGoogle Scholar
  18. 18.
    An JY, Kang TH, Choi MG, Noh JH, Sohn TS, et al. Borrmann type IV: an independent prognostic factor for survival in gastric cancer. J Gastrointest Surg. 2008;12(8):1364–9.PubMedCrossRefGoogle Scholar
  19. 19.
    International Union Against Cancer. In: Sobin LH, Wittekind CH, editors. TNM classification of malignant tumors. 5th ed. New York: Wiley; 1997.Google Scholar
  20. 20.
    Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma. 2nd English edition. Gastric Cancer. 1998;1:10–24.PubMedCrossRefGoogle Scholar
  21. 21.
    Teramoto K, Tada M, Tamoto E, Abe M, Kawakami A, Komuro K, et al. Prediction of lymphatic invasion/lymph node metastasis, recurrence, and survival in patients with gastric cancer by cDNA array-based expression profiling. J Surg Res. 2005;124:225–36.PubMedCrossRefGoogle Scholar
  22. 22.
    Rabin I, Chikman B, Lavy R, Sandbank J, Maklakovsky M, Gold-Deutch R, et al. Gastrointestinal stromal tumors: a 19 year experience. Isr Med Assoc J. 2009;11(2):98–102.PubMedGoogle Scholar
  23. 23.
    An JY, Ha TK, Noh JH, Sohn TS, Kim S. Proposal to subclassify stage IV gastric cancer into IVA, IVB, and IVM. Arch Surg. 2009;144(1):38–45. discussion 45.PubMedCrossRefGoogle Scholar
  24. 24.
    Li C, Yan M, Chen J, Xiang M, Zhu ZG, Lin YZ. Prognostic influence of sub-stages according to pTNM categories in patients with stage IV gastric cancer. J Surg Oncol. 2009;99(6):324–8.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Bin Yang
    • 1
  • Guoqiang Wu
    • 2
  • Xiaochen Wang
    • 3
  • Xuefeng Zhang
    • 2
  1. 1.Department of General SurgeryThe 210th Hospital of PLADalianChina
  2. 2.Department of General SurgeryThe General Hospital of ShenYang Military Area CommandShenyangChina
  3. 3.Department of Medical AdministrationThe General Hospital of ShenYang Military Area CommandShenyangChina

Personalised recommendations